Trial reportNature medicine2023
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.JAMA · 2025Pooled it
- Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes-Randomized Controlled Trial (PRISM-RCT) in Chinese patients with young-onset diabetes: design, methods and baseline characteristics.BMJ open diabetes research & care · 2024Trial
- Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches.Diabetologia · 2026Review
- Type 2 diabetes prevention across the life course.Nature medicine · 2026Review
- Review
- Improving Precision Diagnosis and Treatment of Diabetes in Low-Resource Settings in Africa Through Structured Clinical Phenotyping: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Perspectives on human adipose tissue: from cellular mechanisms to clinical complications.Diabetologia · 2026Review
- Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA.Diabetologia · 2026Article
- A generalist precision medication framework using temporal causal inference based on treatment-free physiological profiles.Nature communications · 2026Article
- Redefining Diabetes and Creating Solutions-The Hong Kong Diabetes Register: Kelly West Award Lecture 2025.Diabetes care · 2026Article
- Five tenets for advancing evidence-based precision medicine.Nature medicine · 2026Review
- Personalized Medicine Interventions for Glycemic Control in Adults With Type 2 Diabetes: A Systematic Review.Cureus · 2026Review
- Knowledge, attitude, and practice toward hepatitis B-related cirrhosis among patients.Scientific reports · 2026Article
- Factors Affecting the Treatment Heterogeneity of PPARγ and Pan-PPAR Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Machine Learning-Based Meta-Regression Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review.Diabetes care · 2026Article
- GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes.PloS one · 2026 · on this mapObservational
- Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data.Diabetologia · 2025Article
- Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.Diabetes, obesity & metabolism · 2025Article
- Reduced Weight Gain with Pioglitazone vs Vildagliptin inDiabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Explainable Prediction of Long-Term Glycated Hemoglobin Response Change in Finnish Patients with Type 2 Diabetes Following Drug Initiation Using Evidence-Based Machine Learning Approaches.Clinical epidemiology · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Precision medicine aims to treat an individual based on their clinical characteristics. A differential drug response, critical to using these features for therapy selection, has never been examined directly in type 2 diabetes. In this study, we tested two hypotheses: (1) individuals with body mass index (BMI) > 30 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.